Market research
CUE Cue Biopharma
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 174M
- P/E ratio
- Not available
- Analyst target
- 115
- Dividend yield
- Not available
- Beta
- 2.47
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US22978P2056
- Market cap
- 174M
- P/E ratio
- Not available
- Analyst target
- 115
- Dividend yield
- Not available
- Beta
- 2.47
About
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CUE discussion.
5 years, 4 months ago
Cue Biopharma, Inc is currently in a long term downtrend where the price is trading 16.9% below its 200 day moving average.
From a valuation standpoint, the stock is 91.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 111.9.
Cue Biopharma, Inc's total revenue sank by 54.7% to $475K since the same quarter in the previous year.
Its net income has dropped by 24.5% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 10.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Cue Biopharma, Inc gets an overall score of 1/5.